Rhein-Minapharm

Rhein-Minapharm Biogenetics is a leading biopharmaceutical company based in Egypt, specializing in the development and manufacture of complex genetically engineered proteins. As a subsidiary of Minapharm Pharmaceuticals, it leverages advanced proprietary technologies, including the Hansenula polymorpha yeast expression system and mammalian cell line platforms, to produce high-quality biologics. The company's portfolio includes essential treatments such as interferons, erythropoietin, and filgrastim, targeting therapeutic areas like hepatology, oncology, and hematology. Rhein-Minapharm is recognized for establishing the first biotech R&D and manufacturing facility of its kind in the Middle East and North Africa (MENA) region, focusing on providing affordable biosimilars and innovative biotherapeutics.